|
Multicenter phase Ib/II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study). |
|
|
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha |
|
|
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha |
|
|
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai |
Consulting or Advisory Role - Asahi Kasei; Ono Pharmaceutical; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Becton Dickinson; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Medicon; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; TERUMO; Yakult Honsha |
|
|
Honoraria - Bayer; Chugai Pharma; Lilly; Merck; Taiho Pharmaceutical; Takeda; Yakult Honsha |
|
|
No Relationships to Disclose |
|
|
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Chugai Pharma; Lilly; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda |
Speakers' Bureau - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Chugai Pharma; Takeda; Tsumura & Co. |
Consulting or Advisory Role - Takeda |
|
|
Honoraria - Bayer; Chugai Pharma; Lilly; Sanofi; Takeda; Yakult Honsha |
Research Funding - Chugai Pharma |